Inflammatory myofibroblastic tumor

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA

Note: this is a rare cancer, see this page for more information. These are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.

1 regimens on this page
1 variants on this page


Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.


All lines of therapy

Crizotinib monotherapy


Study Dates of enrollment Evidence
Gambacorti-Passerini et al. 2018 (PROFILE 1013) 2011-03 to 2013-10 Phase 1b, fewer than 20 pts in this subgroup (RT)

Biomarker eligibility criteria

  • ALK+

Targeted therapy

21-day cycles


  1. PROFILE 1013: Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol. 2018 May;93(5):607-614. Epub 2018 Feb 8. link to original article link to PMC article contains dosing details in manuscript PubMed NCT01121588